GET DAILY SIGNALSGyre Therapeutics (GYRE) Q3 2026 Earnings: Revenue Stability Meets Pipeline Milestones
Key Takeaways
- Gyre Therapeutics reported third quarter 2026 revenue of $32.9 million, roughly flat compared with $32.7 million in the same period a year earlier.
- GAAP basic loss per share was $(0.04), compared with basic earnings of $0.01 per share in the prior-year quarter.
- Net loss attributable to common stockholders widened to $4.1 million from net income of $1.0 million a year ago, driven by higher research and development and general and administrative spending.
- The company affirmed its full-year 2026 revenue guidance of $100.5 million to $111.0 million.
- Sales of the lead commercial product ETUARY rose to $31.4 million from $27.7 million a year earlier, offsetting declines in Etorel and Contiva.
- Regulatory momentum continued as the company completed China's NMPA site inspection for F351, with a decision expected in late 2026 or early 2027.
Earnings Context and Why It Matters
Gyre Therapeutics is a U.S.-listed biopharmaceutical company with commercial operations in China focused on fibrosis therapies. Its third quarter 2026 results, released on November 5, 2026, matter because they show how the company's commercial portfolio is holding up while it pivots toward a high-stakes regulatory milestone for its lead candidate F351 (hydronidone). The quarter also reflects the first full period of absorbing Cullgen, the targeted protein degrader company Gyre acquired earlier in 2026, which has meaningfully lifted operating expenses. Investors are weighing steady but modest top-line performance against a swing from profitability to losses, making the durability of product revenue and progress on pipeline catalysts central to the story. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, Gyre Therapeutics reported total revenue of $32.9 million, compared with $32.7 million in the prior-year period. Product-level results were mixed: ETUARY sales increased to $31.4 million from $27.7 million, while Etorel revenue declined to $1.0 million from $1.5 million and Contiva fell to $0.1 million from $1.2 million, reflecting the impact of China's national centralized procurement program.
GAAP basic loss per share was $(0.04), versus basic earnings per share of $0.01 a year earlier. Net loss attributable to common stockholders was $4.1 million, compared with net income of $1.0 million in the same quarter last year. The swing stemmed from higher operating costs, including research and development expense of $8.5 million and general and administrative expense of $8.9 million, up 39% year over year. On an adjusted basis, results came in ahead of consensus expectations, which had projected a wider loss.
Management reaffirmed full-year 2026 revenue guidance of $100.5 million to $111.0 million.
Market Reaction and Investor Sentiment
The stock has been under pressure through much of 2026, losing roughly 37% of its value since the start of the year, against a gain in the broader market. Following the November 5 report, shares declined about 9.7%, closing near $4.01. The muted reaction suggests investors are focusing less on the modest revenue beat and more on the widening net loss and elevated spending tied to the Cullgen integration. Sentiment heading into the quarter had been cautious, with analyst estimates calling for a loss. The real driver of the stock in the near term is likely to be regulatory news on F351 rather than quarterly profitability.
Forward Outlook and Key Factors to Monitor
The most important near-term catalyst is the regulatory decision on F351 (hydronidone) for chronic hepatitis B (CHB)-induced liver fibrosis. Gyre completed the NMPA site inspection during the third quarter, and management expects a decision around late 2026 or early 2027. Approval would represent the company's most significant pipeline event and a major commercial expansion opportunity in China.
Investors should also track the progression of the Cullgen-derived pipeline. Gyre plans to initiate a Phase 2 study of CG001419 for cancer-related bone pain in China in the first half of 2027, while Phase 1 dose-escalation data for CG009301 in high-risk hematologic malignancies is expected in the second half of 2027. IND applications for CG923308 and CG620953 are anticipated around mid-2027.
On the financial side, watch whether ETUARY growth can continue to offset softness in Etorel and Contiva amid China's procurement environment. Cost control and cash preservation also remain in focus, with total cash, deposits, and short-term investments of roughly $98.8 million as of September 30, 2026. How effectively management balances R&D spending against that balance sheet will shape investor confidence through 2027.
Exploring Tickeron’s AI Screener for Stock Analysis
In my research process, I often turn to Tickeron’s AI Screener to quickly filter opportunities based on technical patterns, fundamentals, and AI-driven signals. It helps surface relevant trade ideas and compare peers efficiently, which proved useful when reviewing Gyre’s results alongside industry trends. The tool supports customizable scans for volatility, performance metrics, and breakout candidates, making it a practical resource during earnings season. Explore the screener to build watchlists tailored to your strategy at https://tickeron.com/app-ng/screener/stocks/diy/industries.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
GYRE in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 30, 2026
GYRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 32 cases where GYRE's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +16.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where GYRE advanced for three days, in 216 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GYRE as a result. In 76 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for GYRE turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 36 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
GYRE moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for GYRE crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for GYRE entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.940) is normal, around the industry mean (2.788). P/E Ratio (-20.050) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (6.536) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. GYRE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 98 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is Corporate Equity?
FAQ: How are the Buy and Sell recommendations formulated on the Tickeron platform?
FAQ: What are the components and creation process of Tickeron's Buy/Sell signals?
Beat the Odds: Ride the Wave of Success with Tickeron's Market-Beating Robot!
How to Trade During War & Market Chaos: Tickeron's Trending Stocks AI Robot — 79%+ Win Rate Signals Across Semiconductors, Defense & Space
General Information
Industry Biotechnology
Advertisement